SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study

This study will consist of two phases, plus a screening period. During the screening period,
subject eligibility for the study will be determined. During Phase 1, qualified participants
will be randomly assigned to one of two elimination diet therapies--the 1FED or the 6FED.
Participants will remain on the assigned dietary therapy for 6 weeks. At the end of 6 weeks
of therapy, esophageal biopsies from participant's standard of care (i.e. normal, routine
care) endoscopy will be evaluated to determine disease status. Participants whose EoE is in
remission (i.e. <15 eos/hpf) will be done with the study.

Participants whose EoE is still active (i.e. ≥15 eos/hpf) will continue into Phase 2 of the
study. During Phase 2, participants who were on 1FED in Phase 1 will receive 6FED therapy for
6 weeks, and participants who were on 6FED during Phase 1 will receive swallowed
glucocorticoid therapy for 6 weeks. At the end of 6 weeks of therapy, esophageal biopsies
from participant's standard of care (i.e. normal, routine care) endoscopy will be evaluated
to determine disease status.

Inclusion Criteria:

- Have diagnosis of EoE (based on consensus criteria)

- Have histologically confirmed active disease >15 eosinophils/hpf in either distal or
proximal esophagus within 4 weeks of screening visit

- Symptomatic (have experienced symptoms within the last month prior to enrollment)

- PPI confirmation

- Have a negative urine pregnancy test at screening if of childbearing potential

Exclusion Criteria:

- Have been treated with topical swallowed steroids within the last 2 months or systemic
steroids within the last 3 months

- Have pathological eosinophilia in segments of the GI tract other than the esophagus
determined by local review

- Have been diagnosed with a GI malabsorption disorder (i.e., Inflammatory bowel
disease, Crohn's disease) or Celiac disease

- Are currently on dietary therapy strictly avoiding milk or on a 6FED

- Have concurrent H pylori gastritis or parasitic infection

- Have history of anaphylaxis to milk (with current avoidance of milk)

- Have previously failed strict dietary therapy clearly documented with one of these
regimens or topical steroid treatment (i.e. have achieved histological remission of
<15 eos/hpf after having been on fluticasone or >1mg budesonide per day.

- Use of investigational drugs within 4 weeks (one month) prior to enrollment

- Are concurrently receiving any of the prohibited medications for the study

- On immunotherapy for pollen (if not on maintenance therapy) or IgE-mediated food
allergy

- Past or current medical problems or findings from physical examination or laboratory
testing that are not listed above, which, in the opinion of the investigator, may pose
additional risks from participation in the study, may interfere with the participant's
ability to comply with study requirements or that may impact the quality or
interpretation of the data obtained from the study.